Research programme: CNS disorders therapeutics - BTG

Drug Profile

Research programme: CNS disorders therapeutics - BTG

Alternative Names: BGC 2031920; Dopamine transport inhibitors - BTG; Monoamine reuptake inhibitors - BTG

Latest Information Update: 23 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BTG
  • Class
  • Mechanism of Action Biogenic monoamine uptake inhibitors; Dopamine plasma membrane transport protein antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cocaine abuse; Major depressive disorder; Parkinson's disease

Most Recent Events

  • 23 Feb 2006 This programme is still in active development
  • 05 Mar 2004 This programme is available for licensing in Europe, North America and Japan (
  • 05 Mar 2004 Preclinical trials in Cocaine abuse in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top